oa Editorial [News in Therapy of Cardiomyopathy (Executive Editor: Giovanni Fazio)]

In the last decade there has been made much progress in defining clinical diagnosis and therapy of cardiomyopathies. Initially, some new types of cardiomyopathies, such as Takotsubo and Non Compaction of the Myocardium Ventricle were better defined, which were then incorporated fully in the guidelines and classification tables. Alongside technological development new diagnostic approaches, have been suggested and thus techniques such as nuclear magnetic resonance to high resolution and three-dimensional CARTO mapping endoventricular are part of the routine diagnostic of Arrhythmogenic right ventricular cardiomyopathy. Three-dimensional echocardiography is suggested as a possible additional tool in the diagnosis of Non Compaction, Delay Enhancement as a parameter able to define the degree of risk of hypertrophic or dilated cardiomyopathy; CT coronary as relevant inquiry in patients with hypertrophic cardiomyopathy to search intramyocardial bridges, and much more. This issue fits into the view, strongly evolution and seeks to analyze these diagnostic therapeutic advances. First, the Tigen et al. have addressed the age-old theme of beta blocker treatment in dilated cardiomyopathy, trying to answer the question “What's the best of all?” [1]. Malato et al. have instead analyzed the forms of dilated cardiomyopathy as a result of a haematological disease presenting the possibility of treatment [2]. In their review the group of Vienna addressed the problem of arrhythmias in noncompaction ventricular myocardium and the problem of treatment of co-morbidity neurological disorders in these patients [3,4]. Palecek et al. and Kida et al. instead have gutted two revisions challenging the long standing issue of treatment in acute and chronic Takotsubo therapy [5, 6]. Corrado et al. have attempted to define the best diagnostic and therapy in arrhythmogenic right ventricular cardiomyopathy in light of current knowledge and their experience [7]. Last work by Mongiovi et al. analyzed aspects of cardiomyopathies in the fetal period, where the diagnosis is complex and treatment almost impossible [8]. In general, this issue is an interesting support for those involved in the diagnosis and treatment of these diseases, and a major upgrade in terms of cardiomyopathies.....